References
- Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis 2003; 36: 1157–611
- Bernard L, Hoffmeyer P, Assal M, Vaudaux P, Schrenzel J, Lew D. Trends in the treatment of orthopedic prosthetic infections. J Antimicrob Chemother 2004; 53: 127–9
- Darley ES, MacGowan AP. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53: 928–35
- Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency Use Study Group. J Antimicrob Chemother 2000; 46: 775–84
- Stein A, Bataille JF, Drancourt M, Curvale G, Argenson JN, Groulier P, Raoult D. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral cotrimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086–91
- Antony SJ, az-Vasquez E, Stratton C. Clinical experience with linezolid in the treatment of resistant Gram-positive infections. J Natl Med Assoc 2001; 93: 386–91
- Daptomycin (Cubicin®) for skin and soft tissue infections. Med Lett Drugs Ther 2004;46:11–2.
- Vaudaux P, Francois P, Bisognano C, Li D, Lew DP, Schrenzel J. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003; 52: 89–95
- Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33: 689–92
- Fantin B, Carbon C. In vivo antibiotic synergism: contribution of animal models. Antimicrob Agents Chemother 1992; 36: 907–12
- Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign Body Infection (FBI) Study Group. JAMA 1998; 279: 1537–41
- Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235–40
- Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 2871–5
- Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530–2
- Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J. Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991 January; 35(1)92–8
- Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003 May; 47(5)1714–8
- Palmer SM, Rybak MJ. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother 1996 March; 40(3)701–5
- Shelburne SA, Musher DM, Hulten K, Ceasar H, Lu MY, Bhaila I, Hamill RJ. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 2004 October; 48(10)4016–9
- Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003 August; 47(8)2538–44
- Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004 March 15; 38(6)864–70